PALI vs. MCRB

The year-to-date returns for both stocks are quite close, with PALI having a -55.03% return and MCRB slightly lower at -57.58%.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Palisade Bio, Inc. (PALI) and Seres Therapeutics, Inc. (MCRB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current PALI Sharpe Ratio is -0.78, which is lower than the MCRB Sharpe Ratio of -0.55. The chart below compares the historical Sharpe Ratios of PALI and MCRB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither PALI nor MCRB has paid dividends to shareholders.

The maximum PALI drawdown since its inception was -100.00%, roughly equal to the maximum MCRB drawdown of -99.34%. Use the drawdown chart below to compare losses from any high point for PALI and MCRB.

The current volatility for Palisade Bio, Inc. (PALI) is 22.71%, while Seres Therapeutics, Inc. (MCRB) has a volatility of 29.70%. This indicates that PALI experiences smaller price fluctuations and is considered to be less risky than MCRB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Palisade Bio, Inc. and Seres Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.